CA Patent

CA2929545C — Dual mechanism inhibitors for the treatment of disease

Assigned to Aerie Pharmaceuticals Inc · Expires 2019-04-09 · 7y expired

What this patent protects

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the meth…

USPTO Abstract

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (10P) may be achieved. Compounds according to the invention include those according to Formula l: (see formula I) wherein B, O, Z, X1, R1, R2, A, R3, X2, and X3, are as defined in the specification.

Drugs covered by this patent

Patent Metadata

Patent number
CA2929545C
Jurisdiction
CA
Classification
—
Expires
2019-04-09
Drug substance claim
No
Drug product claim
No
Assignee
Aerie Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.